Latest news with #CSL
Business Upturn
17 hours ago
- Business
- Business Upturn
Cochin Shipyard secures order for two 70 T Bollard Pull Tugs from Polestar Maritime
Cochin Shipyard Limited (CSL), one of India's premier shipbuilders, has recently informed exchanges that the company secured a fresh order from Polestar Maritime Limited for the construction of two powerful 70-ton Bollard Pull Tugs. These vessels are expected to be delivered in May 2027 and September 2027, respectively. This new order comes on top of three similar tugs already under construction by Udupi Cochin Shipyard Limited (Udupi-CSL), a wholly owned CSL subsidiary. Polestar Maritime, a well-known name in harbour tug services and marine assistance across ports, is expanding its fleet with high-performance, India-built vessels. The tugs will be built based on designs by Robert Allan Ltd., a global leader in tugboat design. Both CSL and Udupi-CSL are playing a key role in bringing these advanced tug designs to India under the Government of India's Approved Standard Tug Design and Specifications (ASTDS) framework—part of the broader 'Atma Nirbhar Bharat' initiative to boost local manufacturing. The vessels will be jointly constructed at CSL's Cochin yard under a work-share model with Udupi-CSL. Each tug will be powered by twin 1838 kW engines and 2.7-meter propellers supplied by Niigata IHI Power Systems, Japan. With four tugs already delivered and 20 more—18 regular and 2 green tugs—in the pipeline, CSL continues to make steady progress in strengthening India's shipbuilding capabilities. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
South China Morning Post
21 hours ago
- Business
- South China Morning Post
Team bus of CSL leaders Beijing Guoan seized over debt issues, players forced to hire bikes
Chinese Super League (CSL) leaders Beijing Guoan have had their team bus seized, forcing players to return from training using shared bikes, as the club's parent company struggles with billions of yuan of debt. Advertisement Pictures on social media on Friday showed the team bus being towed away with its door bearing a seal from the Beijing Intermediate People's Court. Images then started circulating on Chinese social media showing three of the club's foreign players hiring shared bikes and riding away from the training complex wearing their kit. The real estate company Sinobo Group holds a 64 per cent stake in Beijing Guoan and reportedly owes more than 3.68 billion yuan (US$502 million). Despite the off-field issues, Guoan invested heavily in the build-up to the 2025 season, including bringing in former Barcelona manager Quique Setien to lead the team, as well as seven first-team players. Three of the club's foreign players have been pictured hiring shared bikes. Photo: Handout At the halfway stage of the current CSL season, Guoan have yet to lose a match, winning 10 and drawing five to top the league on goal difference. Shanghai Shenhua are second.
ABC News
2 days ago
- Health
- ABC News
US Health Secretary Kennedy's vaccine panel backs preservative-free flu shot
US Health Secretary Robert Kennedy Jr's vaccine advisory panel has recommended Americans receive seasonal influenza shots that are free from thimerosal. Thimerosal is only used in multi-dose vials of flu shots in the US during the 2024-25 flu season, despite decades of studies showing no related safety issues. Fewer than 5 per cent of the flu shots administered were from such vials, according to the US Food and Drug Administration (FDA). Anti-vaccine groups have linked thimerosal to autism and other neurodevelopmental disorders for decades. Mr Kennedy wrote a book in 2014 in which he advocated for "the immediate removal of mercury" from vaccines. In recent days, he has posted on X about its alleged dangers. On its website, the FDA said: "There was no evidence that thimerosal in vaccines was dangerous." The decision to remove it previously was a precautionary measure to decrease overall exposure to mercury among young infants, it added. Multi-dose forms of CSL's Afluria and Flucelvax as well as Sanofi's Fluzone use thimerosal as a preservative, according to the FDA's website. Paris-headquartered Sanofi said it would have sufficient supply of its flu vaccine to support customer preference for this season. CSL said it supplies a very low number of multi-dose vials of flu vaccine in response to demand. The Centers for Disease Control and Prevention (CDC) staff concluded in a report that evidence did not support an association between thimerosal-containing vaccines and autism or other neurodevelopmental disorders. The report was briefly published and then removed from the meeting's online document site. Panel member Dr Robert Malone said the directive to remove the staff report came from Mr Kennedy's office. The panel, called the Advisory Committee on Immunization Practices (ACIP), voted 5-1 in three separate votes to recommend thimerosal-free shots. The now seven-person panel was installed by Mr Kennedy earlier this month after he fired all 17 previous ACIP outside experts. The panel advises the CDC on who should take specific vaccines and related products and when they should be given after FDA approval. It typically meets three times a year and intends to conduct its next meeting in the third quarter, the centres say. "The risk from influenza is so much greater than the nonexistent — as far as we know — risk from thimerosal," Dr Cody Meissner, the only panel member who voted against the recommendation, said in explaining his vote. Lyn Redwood, formerly of the Kennedy-founded anti-vaccine group Children's Health Defense, gave the presentation on thimerosal, arguing that it was a neurotoxin. Ms Redwood's presentation posted on the CDC's website earlier this week initially included a reference to a study that does not exist. The report she presented to the committee was significantly shorter, removing a slide that made a reference to that study and another saying she did not have any conflicts of interest. "With the vote on thimerosal this afternoon, the new committee has turned the ACIP process into a farce," said former CDC vaccine adviser Dr Fiona Havers, who resigned last week over Mr Kennedy's changes to vaccine policy. She said it is unprecedented to have an outside speaker present and then move immediately to a vote. Evidence is usually compiled formally by the CDC and reviewed by a work group, Dr Havers said. She added that CDC experts did not present their data publicly to refute Ms Redwood. CBS and The New York Times have reported that the agency hired Dr Redwood to work in its vaccine safety office. On Thursday, the committee voted 5-2 to recommend use of Merck's MRK.N recently approved RSV antibody drug Enflonsia for infants eight months or younger whose mothers did not receive a preventive shot during pregnancy. ACIP panel member Retsef Levi raised safety concerns about the antibody drug, which were addressed by experts at the FDA and CDC. He said he would be concerned about giving the product to one of his healthy children and was one of the two votes against the recommendation. The panel's recommendations need to be adopted by either the CDC director or the Health and Human Services Secretary before becoming final. There is currently no CDC director. US President Donald Trump's nominee for the post, Susan Monarez, spoke to a Senate committee yesterday as part of the confirmation process. ABC/Reuters
Business Recorder
2 days ago
- Business
- Business Recorder
Australian shares wipe out early gains as banks drag
Australian shares gave up early gains to close lower on Friday, as losses in heavyweight financials offset a rise in mining stocks, but the benchmark still posted a weekly gain. The S&P/ASX 200 index ended 0.4% lower to finish the session at 8,514.2 points after rising as much as 0.6% in the early hours of trade. The benchmark gained 0.1% for the week and was poised to log its third consecutive monthly gain. Banking stocks fell 1.5% after hitting a fresh peak for the fourth straight session, with the 'big four' banks losing between 1.6% and 2.8%. However, the sub-index marked its strongest week in nearly a month. 'Financials have taken a breather after a strong run. This looks like a classic case of profit-taking rather than a shift in fundamentals — banks remain well-supported by stable credit conditions and a resilient domestic economy,' said Hebe Chen, market analyst at Vantage Markets. Healthcare stocks also fell 1.4%, with biotech firm CSL losing 2%. The sub-index lost 1.5% for the week, its weakest since early May. Australian shares close lower as tech stocks weigh 'As appetite for defensives fades and investors rotate into more cyclical names, CSL's lackluster performance continues to deter any meaningful dip-buying,' Chen said. Real estate stocks fell 1.2%, while the industrial sector was down 0.7%. Bucking the trend, heavyweight mining stocks rose 2.5% and posted their strongest session since April 10. The sub-index rose 0.3% for the week, its best weekly performance in more than a month. Dalian iron ore futures rose and were poised for a weekly gain on falling iron ore and steel inventories. Sector giant BHP rose 3.9%, closing at its highest level since June 12. Rio Tinto and Fortescue added 4.6% and 3.6%, respectively, on the day. New Zealand's benchmark S&P/NZX 50 index closed the session 0.8% higher at 12,583.59 points, extending gains for the week.
Mint
2 days ago
- Business
- Mint
Australian shares wipe out early gains as banks drag
Banks fall while miners gain NZ50 gains for second straight week (Updates to market close) June 27 (Reuters) - Australian shares gave up early gains to close lower on Friday, as losses in heavyweight financials offset a rise in mining stocks, but the benchmark still posted a weekly gain. The S&P/ASX 200 index ended 0.4% lower to finish the session at 8,514.2 points after rising as much as 0.6% in the early hours of trade. The benchmark gained 0.1% for the week and was poised to log its third consecutive monthly gain. Banking stocks fell 1.5% after hitting a fresh peak for the fourth straight session, with the "big four" banks losing between 1.6% and 2.8%. However, the sub-index marked its strongest week in nearly a month. "Financials have taken a breather after a strong run. This looks like a classic case of profit-taking rather than a shift in fundamentals — banks remain well-supported by stable credit conditions and a resilient domestic economy," said Hebe Chen, market analyst at Vantage Markets. Healthcare stocks also fell 1.4%, with biotech firm CSL losing 2%. The sub-index lost 1.5% for the week, its weakest since early May. "As appetite for defensives fades and investors rotate into more cyclical names, CSL's lackluster performance continues to deter any meaningful dip-buying," Chen said. Real estate stocks fell 1.2%, while the industrial sector was down 0.7%. Bucking the trend, heavyweight mining stocks rose 2.5% and posted their strongest session since April 10. The sub-index rose 0.3% for the week, its best weekly performance in more than a month. Dalian iron ore futures rose and were poised for a weekly gain on falling iron ore and steel inventories. Sector giant BHP rose 3.9%, closing at its highest level since June 12. Rio Tinto and Fortescue added 4.6% and 3.6%, respectively, on the day. New Zealand's benchmark S&P/NZX 50 index closed the session 0.8% higher at 12,583.59 points, extending gains for the week. (Reporting by Nikita Maria Jino in Bengaluru; Editing by Vijay Kishore)
